Lucigen announced today that it has been acquired by LGC, an international, privately owned company in the extended life sciences sector that seeks to strengthen its reagents offering in the genomics market.

“Our two organizations share the same passion to innovate and delivery to customers,” Lucigen CEO Ralph Kauten said in a statement. “Being part of a larger, global group will enable us to further expand our reach to new markets, while still focusing on delighting our customers and providing technology leading products.”

According to a release, LGC will further develop Lucigen’s capabilities and offerings at its Middleton, Wis., site.

LGC is headquartered in London and operates out of 19 countries.